It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The role of miRNAs in cancer and their possible function as therapeutic agents are interesting and needed further investigation. The miR-26a-5p had been demonstrated as a tumor suppressor in various cancers. However, the importance of miR-26a-5p regulation in upper tract urothelial carcinoma (UTUC) remains unclear. Here, we aimed to explore the miR-26a-5p expression in UTUC tissues and to identify its regulatory targets and signal network involved in UTUC tumorigenesis. The miR-26a-5p expression was validated by quantitative real-time polymerase chain reaction (qPCR) using renal pelvis tissue samples from 22 patients who were diagnosed with UTUC and 64 cases of renal pelvis tissue microarray using in situ hybridization staining. BFTC-909 UTUC cells were used to examine the effects of miR-26a-5p genetic delivery on proliferation, migration and expression of epithelial-to-mesenchymal transition (EMT) markers. MiR-26a-5p was significantly down-regulated in UTUC tumors compared to adjacent normal tissue and was decreased with histological grades. Moreover, restoration of miR-26a-5p showed inhibition effects on proliferation and migration of BFTC-909 cells. In addition, miR-26a-5p delivery regulated the EMT marker expression and inhibited WNT5A/β-catenin signaling and expression of downstream molecules including NF-κB and MMP-9 in BFTC-909 cells. This study demonstrated that miR-26a-5p restoration may reverse EMT process and regulate WNT5A/β-catenin signaling in UTUC cells. Further studies warranted to explore the potential roles in biomarkers for diagnostics and prognosis, as well as novel therapeutics targets for UTUC treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Urology, Kaohsiung, Taiwan, ROC (GRID:grid.145695.a) (ISNI:0000 0004 1798 0922); Kaohsiung Medical University, Department of Medical Laboratory Science and Biotechnology, Kaohsiung, Taiwan, ROC (GRID:grid.412019.f) (ISNI:0000 0000 9476 5696); National Sun Yat-Sen University, Institute of Biomedical Sciences, Kaohsiung, Taiwan, ROC (GRID:grid.412036.2) (ISNI:0000 0004 0531 9758)
2 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Urology, Kaohsiung, Taiwan, ROC (GRID:grid.145695.a) (ISNI:0000 0004 1798 0922)
3 E-Da Hospital, Department of Medical Research, Kaohsiung, Taiwan, ROC (GRID:grid.414686.9) (ISNI:0000 0004 1797 2180)
4 Kaohsiung Medical University, Department of Medical Laboratory Science and Biotechnology, Kaohsiung, Taiwan, ROC (GRID:grid.412019.f) (ISNI:0000 0000 9476 5696)
5 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Pathology, Kaohsiung, Taiwan, ROC (GRID:grid.145695.a) (ISNI:0000 0004 1798 0922)
6 National Sun Yat-Sen University, Institute of Biomedical Sciences, Kaohsiung, Taiwan, ROC (GRID:grid.412036.2) (ISNI:0000 0004 0531 9758)